申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
公开号:US10106556B2
公开(公告)日:2018-10-23
The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.
The present invention relates a compound represented by the formula (I):
wherein each symbol is as described in the specification,
or a salt thereof.
本发明提供了一种具有 MAGL 抑制作用的化合物,该化合物有望用作预防或治疗神经退行性疾病(如阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化症、脑外伤、青光眼、多发性硬化症等)的药物、阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩性脊髓侧索硬化症、脑外伤、青光眼、多发性硬化症等)、焦虑症、疼痛(如炎性疼痛、癌性疼痛、神经源性疼痛等)、癫痫、抑郁症等。
本发明涉及一种由式(I)代表的化合物:
其中各符号如说明书所述、
或其盐类。